Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranexa Advisory Cmte. Review Cancelled; User Fee Date May Be Extended

Executive Summary

CV Therapeutics sees a Ranexa action letter or a user fee date extension as FDA's next possible steps following the cancellation of the angina agent's September review by FDA's Cardiovascular & Renal Drugs Advisory Committee
Advertisement

Related Content

Ranexa Restricted Angina Indication Would Require New Study, Cmte. Says
October User Fee Lineup Includes 7 NMEs; Many Expect “Approvable” Action
October User Fee Lineup Includes 7 NMEs; Many Expect “Approvable” Action
CV Therapeutics Ranexa Pre-Launch Steps Will Ramp Up After Cmte. Review
CV Therapeutics Ranexa Pre-Launch Steps Will Ramp Up After Cmte. Review
Sanofi UroXatral Approval For BPH Includes Phase IV QT Study Commitment
Ranexa Run-Up Shows Breadth Of Biotech Rally On Wall Street
Levitra, UroXatral Clear Safety Hurdle; Labels Should Describe QT Effect
Advertisement
UsernamePublicRestriction

Register

PS042296

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel